I got married in 2014. I remember waking up with numb feet a couple months after we bought our house. But I didn’t think much of it at the time. I could always feel the floor again once I’d finished ...

Multiple sclerosis (MS) is a central nervous system (CNS) disorder that involves inflammation, demyelination, and degenerative changes that eventually lead to disability if untreated. 1 Approximately ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...

—A team of Italian investigators recently used magnetic resonance imaging to classify the cognitive features of multiple sclerosis patients into 5 distinct phenotypes, possibly opening the door to ...

On December 28, 2022, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), a disease-modifying therapy (DMT) to treat relapsing forms of multiple sclerosis (RMS) in adults, ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...